Skip to main content

Loading market data...

AGIO

Agios Pharmaceuticals, Inc.

NASDAQ • United states

$34.90

+$3.58

(+11.43%)

Source: Yahoo Finance · Quote time Oct 19, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Agios Pharmaceuticals, Inc. (AGIO)

Unavailable

Quotes may be delayed

$2.08B

Market Cap

1,972,948

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Agios Pharmaceuticals, Inc. Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: 88 SIDNEY STREET, CAMBRIDGE, MA
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

3 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Agios Pharmaceuticals, Inc..

30 Jul 2026

Agios Pharmaceuticals, Inc. filed Form 10-Q

Agios Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

30 Jul 2026

Agios Pharmaceuticals, Inc. reported Operating or financial results

Agios Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

2 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Agios Pharmaceuticals, Inc..

18 Jun 2026

Agios Pharmaceuticals, Inc. securities registration filing

Agios Pharmaceuticals, Inc. filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$99.65M

Total assets (USD)$1.11B

Total liabilities (USD)$82.40M

Shareholders' equity (USD)$1.03B

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$44.75M	−$110.55M	−$100.70M	−$1.69	10-Q · 30 Jul 2026
Q1 2026	$20.75M	−$110.03M	−$99.11M	−$1.69	10-Q · 29 Apr 2026
Q4 2025	$19.97M	−$121.58M	−$108.26M	Unavailable	10-K · 12 Feb 2026
Q3 2025	$12.88M	−$116.87M	−$103.43M	−$1.78	10-Q · 30 Oct 2025
Q2 2025	$12.46M	−$127.06M	−$112.02M	−$1.93	10-Q · 31 Jul 2025
Q1 2025	$8.73M	−$106.63M	−$89.29M	−$1.55	10-Q · 1 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $43.00

23.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

5

⏸️

Hold

2

📉

Sell

0

7 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 20 Oct 2026, 11:49 UTC Targets range 32.00–55.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

4

Aug 2026

Gheuens Sarah

Chief Medical Officer

Open-market sale

$30.48 per share

30,000 shares

8

Jul 2026

Backstrom Jay T.

Director

Grant or award

Unavailable per share

1,447 shares

1

Jul 2026

Gheuens Sarah

Chief Medical Officer

Option exercise

Unavailable per share

8,375 shares

1

Jul 2026

Gheuens Sarah

Chief Medical Officer

Open-market sale

$37.56 per share

4,007 shares

18

Jun 2026

Ballal Rahul D.

Director

Option exercise

Unavailable per share

2,816 shares

18

Jun 2026

CAPELLO JEFFREY D

Director

Option exercise

Unavailable per share

2,816 shares

18

Jun 2026

Foster-Cheek Kaye I

Director

Option exercise

Unavailable per share

2,816 shares

18

Jun 2026

FOUSE JACQUALYN A

Director

Option exercise

Unavailable per share

2,816 shares

18

Jun 2026

Ho Maykin

Director

Option exercise

Unavailable per share

2,816 shares

Top Shareholders

Blackrock, Inc.

6,455,997 shares

12.181% change

6/30/2026

Farallon Capital Management, L.L.C.

5,917,400 shares

4.106% change

6/30/2026

Vanguard Group Inc

5,594,353 shares

-0.188% change

12/31/2025

State Street Corp

3,533,633 shares

5.015% change

6/30/2026

Lynx1 Capital Management Lp

3,408,937 shares

30.532% change

6/30/2026

D. E. Shaw & Co., Inc.

3,107,005 shares

15.882% change

6/30/2026

Vanguard Portfolio Management Llc

2,898,197 shares

10.998% change

6/30/2026

Vanguard Capital Management Llc

2,681,845 shares

1.882% change

6/30/2026

Armistice Capital, Llc

2,400,000 shares

-11.635% change

6/30/2026

Erste Asset Management Gmbh

2,154,900 shares

-20.333% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 20 Oct 2026, 11:50 UTC· 1 day ago

Research coverage and investment tools

Agios Pharmaceuticals, Inc. (AGIO) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$34.90 on 19 Oct 2026. That is 53% of the way from its 52-week low of US$22.24 to its 52-week high of US$46.00. Its market capitalisation was US$2.08 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$44.75M	−$110.55M	−$100.70M	−$1.69	—	-247.1%	−$58.52M	10-Q · 30 Jul 2026 (opens in a new tab)
Q1 2026	$20.75M	−$110.03M	−$99.11M	−$1.69	—	-530.3%	−$119.69M	10-Q · 29 Apr 2026 (opens in a new tab)
Q4 2025	$19.97M	−$121.58M	−$108.26M	Unavailable	—	-608.9%	−$97.33M	10-K · 12 Feb 2026 (opens in a new tab)
Q3 2025	$12.88M	−$116.87M	−$103.43M	−$1.78	—	-907.4%	−$89.71M	10-Q · 30 Oct 2025 (opens in a new tab)
Q2 2025	$12.46M	−$127.06M	−$112.02M	−$1.93	—	-1,020.1%	−$78.00M	10-Q · 31 Jul 2025 (opens in a new tab)
Q1 2025	$8.73M	−$106.63M	−$89.29M	−$1.55	—	-1,222.0%	−$112.26M	10-Q · 1 May 2025 (opens in a new tab)

Quarter ended	Reported	EPS	Consensus	Surprise
Jun 2026	7/30/2026	−$1.69	−$1.86	+9.1%
Mar 2026	4/29/2026	−$1.69	−$1.81	+6.6%
Dec 2025	2/12/2026	−$1.85	−$1.97	+6.1%
Sep 2025	10/30/2025	−$1.78	−$1.93	+7.8%

Cash and equivalents: $99.65M
Total assets: $1.11B
Total liabilities: $82.40M
Shareholders' equity: $1.03B

SCHEDULE 13G/A · 3 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Agios Pharmaceuticals, Inc..
10-Q · 30 Jul 2026

Agios Pharmaceuticals, Inc. filed Form 10-Q (opens in a new tab)

Agios Pharmaceuticals, Inc. submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 30 Jul 2026

Agios Pharmaceuticals, Inc. reported Operating or financial results (opens in a new tab)

Agios Pharmaceuticals, Inc. filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G · 2 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Agios Pharmaceuticals, Inc..
S-8 · 18 Jun 2026

Agios Pharmaceuticals, Inc. securities registration filing (opens in a new tab)

Agios Pharmaceuticals, Inc. filed a registration or prospectus document concerning securities.

Insider	Date	Transaction	Shares	Average price	Filing
Gheuens Sarah Chief Medical Officer	4 Aug 2026	Open-market sale (S)	−30,000	$30.48	Form 4 (opens in a new tab)
Backstrom Jay T. Director	8 Jul 2026	Grant or award (A)	+1,447	—	Form 4 (opens in a new tab)
Gheuens Sarah Chief Medical Officer	1 Jul 2026	Option exercise (M)	+8,375	—	Form 4 (opens in a new tab)
Gheuens Sarah Chief Medical Officer	1 Jul 2026	Open-market sale (S)	−4,007	$37.56	Form 4 (opens in a new tab)
Ballal Rahul D. Director	18 Jun 2026	Option exercise (M)	+2,816	—	Form 4 (opens in a new tab)
CAPELLO JEFFREY D Director	18 Jun 2026	Option exercise (M)	+2,816	—	Form 4 (opens in a new tab)
Foster-Cheek Kaye I Director	18 Jun 2026	Option exercise (M)	+2,816	—	Form 4 (opens in a new tab)
FOUSE JACQUALYN A Director	18 Jun 2026	Option exercise (M)	+2,816	—	Form 4 (opens in a new tab)
Ho Maykin Director	18 Jun 2026	Option exercise (M)	+2,816	—	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Blackrock, Inc.	6/30/2026	6,455,997	12.181%
Farallon Capital Management, L.L.C.	6/30/2026	5,917,400	4.106%
Vanguard Group Inc	12/31/2025	5,594,353	-0.188%
State Street Corp	6/30/2026	3,533,633	5.015%
Lynx1 Capital Management Lp	6/30/2026	3,408,937	30.532%
D. E. Shaw & Co., Inc.	6/30/2026	3,107,005	15.882%
Vanguard Portfolio Management Llc	6/30/2026	2,898,197	10.998%
Vanguard Capital Management Llc	6/30/2026	2,681,845	1.882%
Armistice Capital, Llc	6/30/2026	2,400,000	-11.635%
Erste Asset Management Gmbh	6/30/2026	2,154,900	-20.333%

Previous close: 31.32 USD
Day range: 31.61 – 35.02 USD
52-week range: 22.24 – 46.00 USD
Volume: 1,972,948
Market cap: $2.08B
Average volume: 1,038,285
EPS (FY 2025, diluted): −7.12 USD
Shares outstanding: 59.70M
Beta (5Y monthly): 0.61

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 19 Oct 2026, 20:00 UTC· 2 days ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:34 UTC· 39 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for AGIO yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.